Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
A phase 3 trial of Socazolimab run by Lee's Pharmaceutical Limited in cervical cancer, now recruiting.
Overview
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06459687 by Lee's Pharmaceutical Limited, with 440 participants planned, started 2024-11-28. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Setting
Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III Study
Phase
Phase 3
Sponsor
Lee's Pharmaceutical Limited
Registry
Enrolled
440